Clinical Research Directory

Inclusion Criteria: 1. Age 18-60 years; 2. Diagnosed multiple sclerosis with relapses or progression and sustained accumulated impairment by a neurologist expert in the field; 3. EDSS score of 3-6 (including 3 and 6); 4. EDSS cerebellar functional score ≥ 3 or EDSS pyramidal functional score ≥3； 5. Evidence of current disease activity; 6. If a patient has previously received a cytotoxic agent (mitoxantrone, cyclophosphamide etc.) they must have normal bone marrow morphology and cytogenetics before being considered eligible for this study ; 7. No evidence of hepatic inflammation or fibrosis; Exclusion Criteria: 1. Patients with evidence of myelodysplasia or other non-autoimmune cytopenia; 2. Patients having received a cytotoxic agent within one month of enrolling in this study; 3. Patient with any active or chronic infection (herpes simplex virus, varicella-zoster virus, cytomegalovirus, EB virus, human immunodeficiency virus, hepatitis virus, syphilis, etc.); 4. Patients having received a cytotoxic agent within one month of enrolling in this study; 5. Patients with a malignant tumor currently or within the last 5 years; 6. Patients with cardiac, renal, pulmonary, hepatic or other organ impairment; 7. Patients whose life expectancy is severely limited by another conditions; 8. Pregnancy or risk of pregnancy; 9. Patients unable to give written informed consent in accordance with research ethics board guidelines.